Liraglutide reduces coronary endothelial cells no-reflow damage through activating MAPK/ERK signaling pathway. (2nd November 2021)

• Record Type: Journal Article
• Authors: Chen, Yi; Liu, Chen; Zhou, Peng; Li, Jiannan; Zhao, Xiaoxiao; Wang, Ying; Chen, Runzhen; Song, Li; Zhao, Hanjun; Yan, Hongbing
• Is Part Of: Journal of receptor and signal transduction research. Volume 41:Number 6(2021)
• Page Start: 553
• Page End: 557
• Publication Date: 2021-11-02
• Subjects: Liraglutide -- coronary endothelial cells damage -- no-reflow -- ERK signaling pathway; Cell receptors -- Periodicals; Cellular signal transduction -- Periodicals; 571.6
• DOI: 10.1080/10799893.2020.1833921
• Languages: English
• ISSNs: 1079-9893

Abstract

Abstract: Coronary no-reflow damage is caused by endothelial cell damage although little drug is available to intervene in coronary no-reflow. Liraglutide is a kind of anti-diabetic drug and its cardioprotective role has been widely reported. In this study, we explored the role of liraglutide in regulating coronary endothelial cell damage. We used hydrogen peroxide to mimic coronary no-reflow damage in vitro . After exposure to hydrogen peroxide, endothelial cells' viability was significantly reduced, an effect that was followed by an increase in cell apoptosis. Interestingly, liraglutide treatment obviously upregulated endothelial cell viability and thus prevented cell apoptosis. Further, we also found that liraglutide inhibited the activation of caspase-3 in hydrogen peroxide-treated endothelial cells. Besides, cellular metabolism, as reflected by mitochondrial membrane potential, was disrupted by hydrogen peroxide and reversed to normal levels with liraglutide. Further, we found that the ERK pathway is a potential downstream effector of liraglutide. Administration of liraglutide significantly promoted the activation of ERK and this effect may contribute to endothelial cell survival. Altogether, our results illustrated that hydrogen peroxide-mediated endothelial cell damage could be attenuated by liraglutide through modulation of the MAPK/ERK signaling pathway. This finding will pave a novel road for the intervention of coronary no-reflow damage in patients suffering from myocardial infarction.